HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
16.31
-1.62 (-9.04%)
Aug 7, 2025, 4:00 PM - Market closed
Theseus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 602.2 | 630.2 | 838 | 426.41 | 356.13 | 227.98 | Upgrade | |
Revenue Growth (YoY) | -1.41% | -24.80% | 96.53% | 19.73% | 56.21% | 11.27% | Upgrade |
Cost of Revenue | 548.44 | 560.99 | 686.45 | 698 | 557.32 | 363.3 | Upgrade |
Gross Profit | 53.76 | 69.21 | 151.55 | -271.59 | -201.19 | -135.32 | Upgrade |
Selling, General & Admin | 96.73 | 112.91 | 133.18 | 136.11 | 127.13 | 61.35 | Upgrade |
Operating Expenses | 73.46 | 112.91 | 133.18 | 136.11 | 127.13 | 61.35 | Upgrade |
Operating Income | -19.7 | -43.71 | 18.38 | -407.69 | -328.32 | -196.67 | Upgrade |
Interest Expense | -2.87 | -2.87 | -0.76 | -0.65 | -0.59 | -0.79 | Upgrade |
Interest & Investment Income | 40.08 | 40.08 | 36.15 | 9.6 | 2.08 | 3.24 | Upgrade |
Earnings From Equity Investments | 35.79 | 46.47 | 47.3 | 49.75 | 60.62 | 79.05 | Upgrade |
Currency Exchange Gain (Loss) | 5.06 | 5.06 | 8.66 | -5.7 | 1.67 | 3.27 | Upgrade |
Other Non Operating Income (Expenses) | 4.02 | 5.13 | 1.65 | -5.97 | -11.89 | 1.22 | Upgrade |
EBT Excluding Unusual Items | 62.38 | 50.17 | 111.37 | -360.67 | -276.43 | -110.69 | Upgrade |
Gain (Loss) on Sale of Investments | 477.46 | - | - | - | 121.31 | - | Upgrade |
Asset Writedown | -4.8 | -4.8 | -5.77 | - | - | - | Upgrade |
Pretax Income | 535.03 | 45.36 | 105.6 | -360.67 | -155.12 | -110.69 | Upgrade |
Income Tax Expense | 67.47 | 7.19 | 4.51 | -0.28 | 11.92 | 4.83 | Upgrade |
Earnings From Continuing Operations | 467.56 | 38.17 | 101.09 | -360.39 | -167.04 | -115.52 | Upgrade |
Net Income to Company | 467.56 | 38.17 | 101.09 | -360.39 | -167.04 | -115.52 | Upgrade |
Minority Interest in Earnings | -0.68 | -0.44 | -0.31 | -0.45 | -27.61 | -10.21 | Upgrade |
Net Income | 466.88 | 37.73 | 100.78 | -360.84 | -194.65 | -125.73 | Upgrade |
Net Income to Common | 466.88 | 37.73 | 100.78 | -360.84 | -194.65 | -125.73 | Upgrade |
Net Income Growth | - | -62.56% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 856 | 855 | 850 | 847 | 793 | 698 | Upgrade |
Shares Outstanding (Diluted) | 873 | 873 | 869 | 847 | 793 | 698 | Upgrade |
Shares Change (YoY) | 2.18% | 0.42% | 2.60% | 6.87% | 13.58% | 4.84% | Upgrade |
EPS (Basic) | 0.55 | 0.04 | 0.12 | -0.43 | -0.25 | -0.18 | Upgrade |
EPS (Diluted) | 0.53 | 0.04 | 0.12 | -0.43 | -0.25 | -0.18 | Upgrade |
EPS Growth | - | -66.28% | - | - | - | - | Upgrade |
Free Cash Flow | -49.66 | -17.44 | 186.65 | -305.26 | -220.62 | -70.02 | Upgrade |
Free Cash Flow Per Share | -0.06 | -0.02 | 0.21 | -0.36 | -0.28 | -0.10 | Upgrade |
Gross Margin | 8.93% | 10.98% | 18.09% | -63.69% | -56.49% | -59.36% | Upgrade |
Operating Margin | -3.27% | -6.93% | 2.19% | -95.61% | -92.19% | -86.27% | Upgrade |
Profit Margin | 77.53% | 5.99% | 12.03% | -84.62% | -54.66% | -55.15% | Upgrade |
Free Cash Flow Margin | -8.25% | -2.77% | 22.27% | -71.59% | -61.95% | -30.71% | Upgrade |
EBITDA | -7.49 | -31.36 | 26.58 | -399.03 | -321.13 | -190.61 | Upgrade |
EBITDA Margin | -1.24% | -4.98% | 3.17% | -93.58% | -90.17% | -83.61% | Upgrade |
D&A For EBITDA | 12.21 | 12.34 | 8.21 | 8.66 | 7.19 | 6.06 | Upgrade |
EBIT | -19.7 | -43.71 | 18.38 | -407.69 | -328.32 | -196.67 | Upgrade |
EBIT Margin | -3.27% | -6.93% | 2.19% | -95.61% | -92.19% | -86.27% | Upgrade |
Effective Tax Rate | 12.61% | 15.86% | 4.27% | - | - | - | Upgrade |
Revenue as Reported | 602.2 | 630.2 | 838 | 426.41 | 356.13 | 227.98 | Upgrade |
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.